Global Type 1 Diabetes (T1D) Market Report, History and Forecast 2024-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Type 1 Diabetes (T1D) Market Report, History and Forecast 2024-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Type 1 diabetes (T1D) is an autoimmune disease that occurs when a person’s pancreas stops producing insulin, the hormone that controls blood-sugar levels. T1D develops when the insulin-producing pancreatic beta cells are mistakenly destroyed by the body’s immune system. The cause of this attack is still being researched, however scientists believe the cause may have genetic and environmental components.
Type 1 Diabetes (T1D) report published by Mr Accuracy reports reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Type 1 Diabetes (T1D) market is projected to reach US$ 2685.2 million in 2034, increasing from US$ 1901.2 million in 2022, with the CAGR of 4.6% during the period of 2024 to 2034. Demand from Children and Adults are the major drivers for the industry.
Sedentary lifestyle, unhealthy diet, lack of exercise and increasing prevalence of diabetes are key driver for Type 1 Diabetes (T1D) market. Insulin therapy is very much essential in the patients who have type 1 diabetes. Rising launch of the novel insulin formulations along with several adjunct therapies will positively impact the insulin acceptance. On the other hand, this chronic disorder poses a significant economic impact owing to the increasing cost of insulin coupled with other conditions such as cardiac disorders, kidney disease among others. While insulin therapy keeps people with T1D alive and can help keep blood-glucose levels within recommended range, it is not a cure, nor does it prevent the possibility of T1D’s serious effects. Although T1D is a serious and challenging disease, long-term management options continue to evolve, allowing those with T1D to have full and active lives. Asia Pacific region recorded the highest growth rate over the forecast period owing to the increasingly sedentary lifestyles, obese population, and improper food habits. North America accounted for more than 50% of the total market share over the forecast period.
Report Scope
This report, based on historical analysis (2024-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Type 1 Diabetes (T1D) market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
Novo Nordisk
Sanofi
Eli Lilly
Merck
Boehringer Ingelheim
Samsung Bioepis
Biocon
Astellas
Janssen
Bristol-Myers Squibb
Lexicon
Sanofi
Segment by Type
Rapid Acting Insulin Analogs
Long Acting Insulin Analogs
Premix Insulin Analogs
Children
Adults
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Each chapter of the report provides detailed information for readers to understand the Type 1 Diabetes (T1D) market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2024 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Type 1 Diabetes (T1D), product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Type 1 Diabetes (T1D) industry.
Chapter 3Historical (2024-2022) and forecast (2024-2034) volume and revenue analysis of Type 1 Diabetes (T1D) in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2024 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Type 1 Diabetes (T1D) introduction, etc. Type 1 Diabetes (T1D) Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13Mr Accuracy reports’s Conclusions of Type 1 Diabetes (T1D) market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by Mr Accuracy reports.
Type 1 Diabetes (T1D) report published by Mr Accuracy reports reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Type 1 Diabetes (T1D) market is projected to reach US$ 2685.2 million in 2034, increasing from US$ 1901.2 million in 2022, with the CAGR of 4.6% during the period of 2024 to 2034. Demand from Children and Adults are the major drivers for the industry.
Sedentary lifestyle, unhealthy diet, lack of exercise and increasing prevalence of diabetes are key driver for Type 1 Diabetes (T1D) market. Insulin therapy is very much essential in the patients who have type 1 diabetes. Rising launch of the novel insulin formulations along with several adjunct therapies will positively impact the insulin acceptance. On the other hand, this chronic disorder poses a significant economic impact owing to the increasing cost of insulin coupled with other conditions such as cardiac disorders, kidney disease among others. While insulin therapy keeps people with T1D alive and can help keep blood-glucose levels within recommended range, it is not a cure, nor does it prevent the possibility of T1D’s serious effects. Although T1D is a serious and challenging disease, long-term management options continue to evolve, allowing those with T1D to have full and active lives. Asia Pacific region recorded the highest growth rate over the forecast period owing to the increasingly sedentary lifestyles, obese population, and improper food habits. North America accounted for more than 50% of the total market share over the forecast period.
Report Scope
This report, based on historical analysis (2024-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Type 1 Diabetes (T1D) market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
By Company
Novo Nordisk
Sanofi
Eli Lilly
Merck
Boehringer Ingelheim
Samsung Bioepis
Biocon
Astellas
Janssen
Bristol-Myers Squibb
Lexicon
Sanofi
Segment by Type
Rapid Acting Insulin Analogs
Long Acting Insulin Analogs
Premix Insulin Analogs
Segment by Application
Children
Adults
Segment by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Each chapter of the report provides detailed information for readers to understand the Type 1 Diabetes (T1D) market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2024 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Type 1 Diabetes (T1D), product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Type 1 Diabetes (T1D) industry.
Chapter 3Historical (2024-2022) and forecast (2024-2034) volume and revenue analysis of Type 1 Diabetes (T1D) in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2024 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Type 1 Diabetes (T1D) introduction, etc. Type 1 Diabetes (T1D) Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13Mr Accuracy reports’s Conclusions of Type 1 Diabetes (T1D) market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by Mr Accuracy reports.
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices